- Micro cap Synthetic Biologics (NYSE:SYN) is up 21% premarket on increased volume on the heels of yesterday's announcement of Q1 results. Its cash balance has eroded to $15.1M, but a Phase 3 study of lead product candidate SYN-010 in irritable bowel syndrome is on tap for H2 following an End-of-Phase 2 meeting with the FDA this summer. Investors are bullish on SYN-010's prospects considering Phase 2 results showed treatment with the modified-release lovastatin significantly reduced methane production and IBS symptoms.